ARPA-H invests $160 million to make custom gene editing routine | STAT
Skip to Main Content
My Account
A decade of reporting from the frontiers of health and medicine
Search
Log In
Try STAT+
My Account
News
Latest
Series & Investigations
Business
Biotech
Pharma
Health Tech
Health Insurance
Hospitals
Medical Devices
Washington
Policy
FDA
NIH
Science
CRISPR
Gene Therapy
Neuroscience
Public Health
Addiction
Covid-19
Abortion
Health Disparities
Infectious Disease
Mental Health
Disease
Cancer
Cardiovascular Disease
Chronic Disease
Diabetes
Alzheimer's
Obesity
Features
Health Care Costs
The Deadliest Drug
Science, Shattered
Newsletters
Opinion
Columns
Adam Feuerstein
Matthew Herper
Ed Silverman
Reports
E-books
Podcasts
Tools & Trackers
CRISPR Tracker
Breakthrough Device Tracker
Generative AI Tracker
Obesity Drug Tracker
Events
Upcoming Events
Summits
Community
STAT Wunderkinds 2026
Video
Advertise
STAT Brand Studio
What's the word?<br>Test your knowledge with our new weekday mini crossword
Start solving
STAT Plus<br>Biotech
ARPA-H launches $160 million effort to develop custom gene editing drugs
Program will fund seven groups over five years in hope of Baby KJ-like successes
Manage alerts for this article
Email this article
Share this article
Jean-Christophe VERHAEGEN / AFP via Getty Images
By Jason Mast<br>July 9, 2026
General Assignment Reporter
Jason Mast
[email protected]
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.
The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.<br>Advertisement
Related Story
STAT Plus: FDA chiefs offer roadmap to expand custom gene-editing treatments like Baby KJ’s
Each team has a deadline of starting clinical trials by year three of the program, although some may start much sooner.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
$39/month<br>Get Started<br>Totals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 months<br>Get Started<br>Then $399/year
Annual
$399
Save 15%
$399/year<br>Get Started<br>Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote<br>Request A Quote<br>Savings start at 25%!
2-10 Users
$300
Annually per user
$300/year<br>Get Started<br>$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Log In
biotechnology, CRISPR, gene editing, Gene therapy, HHS, rare diseases, STAT+
Submit a correction requestReprints
Jason Mast
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
Please enter a valid email address.<br>Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Recommended
Biotech
Biotech<br>July 12, 2026
STAT Plus: Tau in the spotlight at Alzheimer’s conference
The Readout
The Readout<br>July 10, 2026
STAT Plus: Roche ends Huntington’s gene-silencing programs
Advertisement
The Readout
The Readout<br>July 9, 2026
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
Adam's Biotech Scorecard<br>July 9, 2026
STAT Plus: 931 days. The drug approval scandal hiding in plain sight
Biotech
Biotech<br>July 9, 2026
STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug
Subscriber Picks
Back to top